Question 1

Am I eligible for this trial based on my cancer type and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC clinical trial (NCT07416058). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this new treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC clinical trial (NCT07416058). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC clinical trial (NCT07416058). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC clinical trial (NCT07416058). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my cancer progresses while participating in the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC clinical trial (NCT07416058). Contact the study team or your healthcare provider for specific answers.

Question 6

Will I need to undergo any specific tests or procedures during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC clinical trial (NCT07416058). Contact the study team or your healthcare provider for specific answers.

What this study is about